Multi-center analytical performance evaluation of the Access Hybritech® p2PSA immunoassay

Clinica Chimica Acta

Volumn 413, Issue 15-16, 2012, Pages 1279-1283

  Sokoll, Lori J ^a   Chan, Daniel W ^a   Klee, George G ^b   Roberts, William L ^c   van Schaik, Ron H N ^d   Arockiasamy, Dorothy A ^e   Broyles, Dennis L ^e   Carlson, Corey M ^e   Mizrahi, Isaac A ^e   Pierson, Tina B ^e   Tam, Jeffrey E ^e  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b MAYO CLINIC   (United States)

^c ARUP LABORATORIES   (United States)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e BECKMAN COULTER INC   (United States)

Author keywords

2 proPSA; Evaluation; ProPSA; Prostate cancer; PSA

Indexed keywords

ALBUMIN; BILIRUBIN; HEMOGLOBIN; PROSTATE SPECIFIC ANTIGEN; TRIACYLGLYCEROL;

ACCURACY; ALBUMIN BLOOD LEVEL; ANTIBODY BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CALIBRATION; COMPARATIVE STUDY; CONTROLLED STUDY; CROSS REACTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMMUNOASSAY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; TRIACYLGLYCEROL BLOOD LEVEL;

HUMANS; IMMUNOASSAY; LUMINESCENT MEASUREMENTS; MALE; PROSTATE-SPECIFIC ANTIGEN; SENSITIVITY AND SPECIFICITY;

EID: 84861330687     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2012.04.015     Document Type: Article

References (21)

1. Mikolajczyk S.D., Marker K.M., Millar L.S., et al. A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res 2001, 61:6958-6963.
2. Mikolajczyk S.D., Marks L.S., Partin A.W., Rittenhouse H.G. Free prostate-specific antigen in serum is becoming more complex. Urology 2002, 59:797-802.
3. Linton H.J., Marks L.S., Millar L.S., Knott C.L., Rittenhouse H.G., Mikolajczyk S.D. Benign prostate-specific antigen (BPSA) in serum is increased in benign prostate disease. Clin Chem 2003, 49:253-259.
4. Peter J., Unverzagt C., Krogh T.N., Vorm O., Hoesel W. Identification of precursor forms of free prostate-specific antigen in serum of prostate cancer patients by immunosorption and mass spectrometry. Cancer Res 2001, 61:957-962.
5. Chan T.Y., Mikolajczyk S.D., Lecksell K. Immunohistochemical staining of prostate cancer with monoclonal antibodies to the precursor of prostate-specific antigen. Urology 2003, 62:177-181.
6. Sokoll L.J., Chan D.W., Mikolajczyk S.D., et al. Proenzyme PSA for the early detection of prostate cancer in the 2.5-4.0ng/ml total PSA range: preliminary analysis. Urology 2003, 61:274-276.
7. Khan M.A., Partin A.W., Rittenhouse H.G., et al. Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0ng/ml. J Urol 2003, 170:723-726.
8. Mikolajczyk S.D., Catalona W.J., Evans C.L., et al. Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer. Clin Chem 2004, 50:1017-1025.
9. Catalona W.J., Bartsch G., Rittenhouse H.G., et al. Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4ng/ml prostate specific antigen. J Urol 2004, 171:2239-2244.
10. Naya Y., Fritsche H.A., Bhadkamkar V.A., Mikolajczyk S.D., Rittenhouse H.G., Babaian R.J. Evaluation of precursor prostate-specific antigen isoform ratios in the detection of prostate cancer. Urol Oncol 2005, 23:16-21.
11. Stephan C., Kahrs A.-M., Cammann H., et al. A [-2]proPSA-based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases. Prostate 2009, 69:198-207.
12. Le B.V., Griffin C.R., Loeb S., et al. [-2] Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study. J Urol 2010, 183:1355-1359.
13. Jansen F.H., Van Schaik R.H., Kurstjens J., et al. Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves the diagnostic accuracy in prostate cancer detection. Eur Urol 2010, 57:921-927.
14. Sokoll L.J., Sanda M.G., Feng Z., et al. A prospective, multicenter, NCI EDRN study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev 2010, 19:1193-1200.
15. Isharwal S., Makarov D.V., Sokoll L., et al. proPSA and diagnostic biopsy tissue DNA content combination improves accuracy to predict the need for prostate cancer treatment among men enrolled in a proactive surveillance program. Urology 2011, 763:e1-e6.
16. Catalona W., Partin A., Sanda M., et al. A multi-center study of [-2]pro-prostate-specific antigen (PSA) in combination with PSA and free PSA for prostate cancer detection in the 2.0 to 10.0ng/ml PSA range. J Urol 2011, 185:1650-1655.
17. Guazzoni G., Lazzeri M., Nava L., et al. Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and Prostate Health Index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer. Eur Urol 2012, 61:455-466.
18. Semjonow A., Köpke T., Eltze E., Pepping-Schefers B., Bürgel B.H., Darte C. Pre-analytical in-vitro stability of [-2]proPSA in blood and serum. Clin Biochem 2010, 43:926-928.
19. Kumar A., Mikolajczyk S.D., Goes A.S., Millar L.S., Saedi M.S. Expression of pro forms of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2. Cancer Res 1997, 57:3111-3114.
20. Laffin R.J., Chan D.W., Tanasijevic M.J., et al. Hybritech total and free prostate-specific antigen assays developed for the Beckman Coulter access automated chemiluminescent immunoassay system: a multicenter evaluation of analytical performance. Clin Chem 2011, 47:129-132.
21. Woodrum D.L., York L. Two year stability of free and total PSA in frozen serum samples. Urology 1998, 52:247-251.